Janssen Cilag

Janssen-Cilag is a major pharmaceutical affiliate family of Johnson & Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson & Johnson). Formed in the early 1990s through the merger of the marketing organizations of Janssen Pharmaceutica and Cilag, the company operates as a key commercialization and clinical development arm across Europe, Latin America, and other global regions. Janssen-Cilag is responsible for a diverse and highly innovative portfolio of approved therapies and late-stage pipeline candidates spanning oncology, immunology, neuroscience, cardiovascular and metabolic diseases, and pulmonary hypertension. Key commercial products marketed by the affiliate include the blockbuster multiple myeloma therapy Darzalex (daratumumab), the CAR-T cell therapy Carvykti (ciltacabtagene autoleucel), the immunology treatment Tremfya (guselkumab), and the newly approved oral peptide Icotyde (icotrokinra) for plaque psoriasis. Through its integration within the broader Johnson & Johnson R&D ecosystem, Janssen-Cilag continues to drive clinical trials and deliver transformative healthcare solutions globally.